Kiselak Tomas
SEC-identified person · CIK 1830177 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Spyre Therapeutics, Inc. SYRE | Director | filed 2023–2026 |
| Jade Biosciences, Inc. JBIO | Director | filed 2025–2026 |
| Apogee Therapeutics, Inc. APGE | Director | filed 2023–2026 |
| Glycomimetics INC GLYC | Director | filed 2025–2026 |
| Oruka Therapeutics, Inc. ORKA | Director | filed 2024–2026 |
| Zenas Biopharma, Inc. ZBIO | Director | filed 2024–2026 |
| Galecto, Inc. GLTO | Officer | filed 2025–2026 |
| Viridian Therapeutics, Inc.\DE VRDN | Director | filed 2020–2025 |
| Magenta Therapeutics, Inc. MGTA | Director | filed 2023–2024 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.